Eastman Kodak's (NYSE:KODK) hopes of becoming a key supplier to the pharmaceutical industry just hit a major snag. The one-time camera and film giant was attempting to use a $765 million loan from the U.S. government to pivot its ailing business. Its plan was to launch Kodak Pharmaceuticals, which would produce pharmaceutical ingredients deemed critical in the fight against COVID-19. Now, those plans have been thrown into disarray. A downwardly sloping stock chart. EASTMAN KODAK'S STOCK PLUMMETED ON NEWS THAT ITS LOAN COULD BE IN JEOPARDY. IMAGE SOURCE: GETTY IMAGES. The Defense Production Act loan was awarded to Kodak by...